We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Albemarle (ALB) Beats Stock Market Upswing: What Investors Need to Know
Read MoreHide Full Article
Albemarle (ALB - Free Report) closed at $106.35 in the latest trading session, marking a +1.9% move from the prior day. This change outpaced the S&P 500's 0.58% gain on the day. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase of 0.45%.
Shares of the specialty chemicals company witnessed a loss of 17.35% over the previous month, trailing the performance of the Basic Materials sector with its loss of 7.2%, and the S&P 500's gain of 0.84%.
The investment community will be closely monitoring the performance of Albemarle in its forthcoming earnings report. The company is scheduled to release its earnings on November 4, 2026. In that report, analysts expect Albemarle to post earnings of $2.55 per share. This would mark year-over-year growth of 1442.11%. Alongside, our most recent consensus estimate is anticipating revenue of $1.52 billion, indicating a 16.07% upward movement from the same quarter last year.
ALB's full-year Zacks Consensus Estimates are calling for earnings of $11.37 per share and revenue of $6.1 billion. These results would represent year-over-year changes of +1539.24% and +18.69%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Albemarle. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.15% lower. At present, Albemarle boasts a Zacks Rank of #4 (Sell).
Looking at its valuation, Albemarle is holding a Forward P/E ratio of 9.18. This represents a discount compared to its industry average Forward P/E of 15.29.
We can also see that ALB currently has a PEG ratio of 0.61. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Chemical - Diversified industry currently had an average PEG ratio of 1.19 as of yesterday's close.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 193, putting it in the bottom 22% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Albemarle (ALB) Beats Stock Market Upswing: What Investors Need to Know
Albemarle (ALB - Free Report) closed at $106.35 in the latest trading session, marking a +1.9% move from the prior day. This change outpaced the S&P 500's 0.58% gain on the day. Meanwhile, the Dow experienced a rise of 0.49%, and the technology-dominated Nasdaq saw an increase of 0.45%.
Shares of the specialty chemicals company witnessed a loss of 17.35% over the previous month, trailing the performance of the Basic Materials sector with its loss of 7.2%, and the S&P 500's gain of 0.84%.
The investment community will be closely monitoring the performance of Albemarle in its forthcoming earnings report. The company is scheduled to release its earnings on November 4, 2026. In that report, analysts expect Albemarle to post earnings of $2.55 per share. This would mark year-over-year growth of 1442.11%. Alongside, our most recent consensus estimate is anticipating revenue of $1.52 billion, indicating a 16.07% upward movement from the same quarter last year.
ALB's full-year Zacks Consensus Estimates are calling for earnings of $11.37 per share and revenue of $6.1 billion. These results would represent year-over-year changes of +1539.24% and +18.69%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Albemarle. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.15% lower. At present, Albemarle boasts a Zacks Rank of #4 (Sell).
Looking at its valuation, Albemarle is holding a Forward P/E ratio of 9.18. This represents a discount compared to its industry average Forward P/E of 15.29.
We can also see that ALB currently has a PEG ratio of 0.61. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Chemical - Diversified industry currently had an average PEG ratio of 1.19 as of yesterday's close.
The Chemical - Diversified industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 193, putting it in the bottom 22% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.